Navigation Links
ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia

SEATTLE, June 04, 2007 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. today announced that interim findings were presented from a Phase 1b clinical trial with atacicept in B-cell chronic lymphocytic leukemia (B-CLL) at the American Society of Clinical Oncology (ASCO) 2007 annual meeting. The study included intravenous administration of higher doses than had been tested in previous studies.

"We found that atacicept was well-tolerated and biologically active at all dose levels in this study, consistent with the results of our other clinical trials," said Douglas E. Williams, Ph.D., Executive Vice President and Chief Scientific Officer of ZymoGenetics. "Together with our partner Merck Serono, we will assess the results of this and our other B-cell malignancy studies, once the studies are complete, to see whether the data support moving forward in these indications."

Atacicept in B-CLL Study Design and Results

In a Phase 1b open-label, dose escalation study, 15 patients with refractory or relapsed disease were given weekly intravenous doses of atacicept ranging from 1 mg/kg to 20 mg/kg, for five weeks. Treatment with atacicept was well tolerated at all dose levels in the study. No dose limiting toxicities or serious adverse events related to study drug have been reported to date. Among the six patients given 10 mg/kg and 15 mg/kg, three (50%) showed signs of disease stabilization, using National Cancer Institute-sponsored Working Group criteria, during the treatment period. Prior to atacicept treatment, all of these patients had rapidly increasing leukocyte counts. One patient, who received 10 mg/kg, exhibited stable disease for over six months.

Biological activity of atacicept was demonstrated in these patients by reduced immunoglobulin (Ig) concentrations after treatment at all dose levels. Mean IgA, IgG and IgM concentrations decreased by 20%, 22% and 15% from baseline, respectively, af
'"/>




Page: 1 2 3

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:9/30/2014)... 30, 2014 Passport Health, one of the ... has launched FluFree.com, a website designed to promote, educate ... For 20 years, Passport Health has provided its clients ... launch of FluFree.com is designed to address the growing ... of people who actually chose to get vaccinated. ...
(Date:9/30/2014)... 2014   Acutus Medical, Inc. (ACM), ... 3D Cardiac Chamber Imaging and Dipole Density Mapping system ... sustain complex cardiac arrhythmias, including atrial fibrillation, announced it ... its imaging/mapping system as well as bring to market ... Medical to complete work on the AcQMap TM ...
(Date:9/30/2014)... , Sept. 30, 2014 Headquartered in ... is a diversified company comprised of several specialized partners ... technology and the proven expertise of its team of ... wellness. WholeHealth Products, line of more than 10 professional ... and its more than 8 retail consumer tests is ...
Breaking Medicine Technology:Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3WholeHealth Products Announces The Discovery Of The "Autism And Fragile X" Microwell And Rapid Diagnostic Test 2
... July 19 Nycomed US Inc. today announced the appointment ... assumes immediate responsibility for Nycomed US Inc., including manufacturing in Melville ... the three marketing and sales divisions Fougera, PharmaDerm and Savage Laboratories. ... Steve Andrzejewski ...
... NEW YORK , July 19 Reportlinker.com announces that a new market research ... , Global Pharma-biotech Alliance ... http://www.reportlinker.com/p0234517/Global-Pharma-biotech-Alliance-Analysis.html , ... This IBD provides an overview of the pharma-biotech alliance deals struck from 2008 to present. ...
Cached Medicine Technology:Steve Andrzejewski Joins Nycomed US Inc. 2Reportlinker Adds Global Pharma-biotech Alliance Analysis 2
(Date:9/30/2014)... A group of Americans is headed to a ... left unchecked, could create a catastrophic, global pandemic. No, it’s ... John Rogers, the Executive Director the Eugene Bell Foundation and ... disease most think mankind conquered long ago: tuberculosis. , “Tuberculosis, ... on the comeback in several countries - what’s especially disconcerting ...
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- Medicare should ... at high risk for the disease, a coalition of ... The coalition, which includes the Lung Cancer Alliance, the ... the American Cancer Society and the American Society of ... Monday to the U.S. Centers for Medicare & Medicaid ...
(Date:9/30/2014)... gene mutation that causes a rare premature aging disease ... the rapid, unstoppable cell division that makes cancer so ... and the U-M Health System recently discovered a protein ... which precious hematopoietic stem cells can,t regenerate and make ... prone to cancer and bone marrow failure. , ...
(Date:9/30/2014)... Healthpointe is proud to announce that ... and ankle reconstruction surgeries to assist patients with severe ... specializes in the diagnosis and treatment of sports medicine, ... also trained to perform advanced Foot and Ankle Reconstruction ... is also fluent in Spanish. , Reconstructive surgical procedures ...
(Date:9/30/2014)... September 30, 2014 Jiwa Law Corporation, a ... that it will now be offering free consultation for personal ... visit the law firm for the first time to meet ... be given the opportunity to understand what their rights are. ... with the client to explain to them what the law ...
Breaking Medicine News(10 mins):Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 2Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 3Health News:Jiwa Law Corporation Now Offers Personal Injury Consultation Without Any Charge 2
... Calif., April 22 DURECT,Corporation (Nasdaq: DRRX ... Executive Officer, will be presenting at the Morgan ... 2008 at 8:30 a.m. ET.,The conference is being ... (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ), A live ...
... Therapeutics,(Amex: CXM ) and its operating unit ... System will be featured on Science,Channel,s "Cool Stuff: ... will,feature InnerCool,s endovascular cooling during a 6-hour brain ... 25, 2008 at 8:00 p.m. (ET/PT). Please,visit ...
... prices have risen,sharply over the last 12 months, organic ... expected to continue in 2008, according to,the Organic Trade ... safer than conventional foods, they are also more expensive.,Because ... looking,to strike a balance between their desire to eat ...
... April 21, 2008 3M Health Care, a leader ... announces plans to introduce the 3M Rapid Detection Flu ... qualitative and objective electronic results in 15 minutes. , ... season, the Rapid Detection Flu Test quickly delivers objective ...
... GeneGo, Inc., the leading,provider of software and databases ... the Chinese University of Hong Kong,Pediatric department will ... drug targets for a large variety of diseases ... to license MetaCore, as well as,species-specific content for ...
... POUGHKEEPSIE, N.Y., April 22 Just in time ... ) is rolling,out a new line of high-end ... -- and the well-being of its customers., ... covers made of bamboo -- a renewable resource ...
Cached Medicine News:Health News:Cardium Announces InnerCool's Endovascular Cooling to be Featured on Science Channel's Series 'Cool Stuff: How It Works' 2Health News:Cardium Announces InnerCool's Endovascular Cooling to be Featured on Science Channel's Series 'Cool Stuff: How It Works' 3Health News:Cardium Announces InnerCool's Endovascular Cooling to be Featured on Science Channel's Series 'Cool Stuff: How It Works' 4Health News:Eat Well, Save Money: BJ's Offers Everyday Low Prices on Top Quality Organic Groceries, Natural Foods Versus Supermarket Prices 2Health News:Eat Well, Save Money: BJ's Offers Everyday Low Prices on Top Quality Organic Groceries, Natural Foods Versus Supermarket Prices 3Health News:3M Health Care announces new 3M Rapid Detection Flu A+B test 2Health News:GeneGo's First Customer in Hong Kong; The Chinese University of Hong Kong 2Health News:Bragada(R) Luxury Mattress, Inc. Goes Green 2
Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl, single-channel with adjustable-volume setting...
... Seven digital models cover the range from ... liquid fluently. Volume lock design prevents inadvertent ... the horizontal grip. Whole pipette is autoclavable ... ejector is all polypropylene. Suitable for one-handed ...
... The Finnpipette Digital offers improved ergonomics ... rounded handle, modified grippy finger rest ... operator comfort and efficiency. Finnpipette Digitals ... power-boosted gearing mechanism (pat. pend.) and ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
Medicine Products: